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Coronary Heart Disease
Association of Proton Pump Inhibitor Use on
Cardiovascular Outcomes With Clopidogrel and Ticagrelor
Insights From the Platelet Inhibition and Patient Outcomes Trial
Shaun G. Goodman, MD, MSc; Robert Clare, MS; Karen S. Pieper, MS; Jose´ C. Nicolau, MD;
Robert F. Storey, MD; Warren J. Cantor, MD; Kenneth W. Mahaffey, MD;
Dominick J. Angiolillo, MD, PhD; Steen Husted, MD; Christopher P. Cannon, MD;
Stefan K. James, MD, PhD; Jan Kilhamn, MD, PhD; P. Gabriel Steg, MD; Robert A. Harrington, MD;
Lars Wallentin, MD, PhD; on behalf of the Platelet Inhibition and Patient Outcomes (PLATO) Trial Investigators
Background—The clinical significance of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear.
Methods and Results—We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular
death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor
in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibition and Patient Outcomes (PLATO) trial. The
primary end point rates were higher for individuals on a PPI (n6539) compared with those not on a PPI (n12 060)
at randomization in both the clopidogrel (13.0% versus 10.9%; adjusted hazard ratio [HR], 1.20; 95% confidence
interval [CI], 1.04–1.38) and ticagrelor (11.0% versus 9.2%; HR, 1.24; 95% CI, 1.07–1.45) groups. Patients on non-PPI
gastrointestinal drugs had similar primary end point rates compared with those on a PPI (PPI versus non-PPI
gastrointestinal treatment: clopidogrel, HR, 0.98; 95% CI, 0.79–1.23; ticagrelor, HR, 0.89; 95% CI, 0.73–1.10). In
contrast, patients on no gastric therapy had a significantly lower primary end point rate (PPI versus no gastrointestinal
treatment: clopidogrel, HR, 1.29; 95% CI, 1.12–1.49; ticagrelor, HR, 1.30; 95% CI, 1.14–1.49).
Conclusions—The use of a PPI was independently associated with a higher rate of cardiovascular events in patients with
acute coronary syndrome receiving clopidogrel. However, a similar association was observed between cardiovascular
events and PPI use during ticagrelor treatment and with other non-PPI gastrointestinal treatment. Therefore, in the
PLATO trial, the association between PPI use and adverse events may be due to confounding, with PPI use more of a
marker for, than a cause of, higher rates of cardiovascular events.
Clinical Trial Registration—http://www.clinicaltrials.gov. Unique identifier: NCT00391872.
(Circulation. 2012;125:978-986.)
Key Words: acute coronary syndrome  clopidogrel  mortality  myocardial infarction  ticagrelor
In patients with both ST-segment and non–ST-segmentelevation acute coronary syndromes (ACS), current clini-
cal practice guidelines recommend the use of dual antiplatelet
therapy with acetylsalicylic acid and P2Y12 inhibition.1,2
Conflicting data exist regarding the potential adverse inter-
action between the effects on clinical events of the P2Y12
inhibitor clopidogrel and proton pump inhibitors (PPIs),
whereas the importance of such an interaction with other
P2Y12 inhibitors is less investigated.
Clinical Perspective on p 986
Several pharmacodynamic studies have shown that some
PPIs reduce the inhibition of platelet aggregation achieved
with clopidogrel treatment.3–10 This phenomenon seems me-
Continuing medical education (CME) credit is available for this article. Go to http://cme.ahajournals.org to take the quiz.
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diated by PPIs with potential to inhibit the cytochrome P450
2C19 (CYP2C19) isoenzyme,11 which plays an important
role in the conversion of clopidogrel into its active metabo-
lite, as shown in pharmacokinetic assessments.4,10 In contrast,
ticagrelor is a directly acting P2Y12 inhibitor not requiring
biotransformation12,13 and with no known interaction with
PPIs.14 In view of the ongoing debate regarding the clinical
significance of the interaction between clopidogrel and
PPIs,15–29 we examined the relationship between PPI use and
cardiovascular outcomes in patients with ACS randomized to
clopidogrel or ticagrelor in a prespecified, nonrandomized
subgroup analysis of the Platelet Inhibition and Patient
Outcomes (PLATO) trial.30,31
Methods
Patients
The PLATO trial was a multicenter, randomized, double-blind,
phase 3 trial in which 18 624 patients were randomly assigned to
clopidogrel (n9291; 300-mg loading dose, 75-mg daily mainte-
nance dose) or ticagrelor (n9333; 180-mg loading dose, 90-mg
twice daily maintenance dose). The details of the study design and
main results have been published previously.30,31 Briefly, patients
hospitalized for an ACS were eligible for enrollment if they had
either ST-segment elevation or new left bundle branch block and
were to undergo primary percutaneous coronary intervention or had
at least 2 of the following: ST-segment deviation; positive biomarker
indicating myocardial necrosis; age 60 years; prior myocardial
infarction (MI) or coronary artery bypass grafting; coronary artery
disease (with 50% stenosis in 2 vessels); prior ischemic stroke,
transient ischemic attack, carotid stenosis (50%), or cerebral revascu-
larization; diabetes mellitus; peripheral arterial disease; or chronic renal
dysfunction (creatinine clearance 60 mL/min per 1.73 m2). Relevant
exclusions to trial participation included an increased risk of bleeding
(eg, active bleeding, major surgery 30 days), clinically important
anemia or thrombocytopenia, the need for ongoing oral anticoagulation
therapy, and moderate/severe liver disease.
PPI and Other Gastric Acid Suppressive Drug Use
The prerandomization and postrandomization (clopidogrel versus
ticagrelor) use of PPI or other gastric acid suppressive therapy (eg,
histamine H2 receptor blockers) was at the discretion of the patient’s
physician(s). For each patient, self-reported use of PPI at the time of
randomization determined the designation of initial PPI status.
Because patients might have initiated or discontinued a PPI during
the course of the trial, several additional sensitivity analyses were
undertaken to assess the risk of adverse outcomes for those receiving
a PPI as captured at different time points and with varying durations
of follow-up. At each patient visit during the course of follow-up
(days 30, 60, 90, and 180), the names of all concomitant medications
were recorded on case report forms.
End Points
The primary end point of the PLATO trial was the 12-month
composite of cardiovascular death, MI, or stroke.30,31 We also
examined secondary end points, including all-cause mortality, car-
diovascular death or nonfatal MI, any MI, stent thrombosis, and
major non–coronary artery bypass grafting bleeding. All efficacy
and safety end points were adjudicated by an independent clinical
events committee who were unaware of the assigned treatment; the
use of a PPI was not specifically concealed.
Statistical Analysis
Baseline characteristics are presented as medians (25th, 75th percen-
tiles) for continuous variables and frequencies for categorical vari-
ables. We compared baseline characteristics between patients receiv-
ing PPI and not receiving PPI at randomization with t tests or
Wilcoxon rank sum tests for continuous variables and with 2 tests
or Fisher exact test for categorical variables.
The evaluation of outcomes by PPI use and randomized treatment
was a prespecified analysis, with the interaction of PPI and treatment
of primary interest. To help to reduce selection bias, the propensity
to receive a PPI before randomization was calculated with multivari-
able logistic regression. The resulting propensity score (conditional
on sex, race, region, peptic ulcer history, previous MI, systolic blood
pressure and heart rate at presentation, hemoglobin, creatinine
clearance, angiotensin-converting enzyme inhibitor and/or angioten-
sin receptor blocker use, statin use, and type of index event [ie,
ST-segment elevation MI, non–ST-segment elevation MI, unstable
angina]) was included in a multivariable Cox proportional hazards
model of each end point to derive adjusted hazard ratios (HRs) and
95% confidence intervals (CIs) with the use of inverse probability
weighting. PPI use, randomized therapy, and the interaction of the 2
were included as covariates.
HRs of individual PPI type at the time of randomization versus no
PPI use within each randomized treatment were generated with a
Cox proportional hazards model that included PPI type, randomized
treatment, and the interaction of the 2 factors. A similar model was
created in which non-PPI use was further divided into non-PPI with
gastrointestinal treatment and non-PPI with no gastrointestinal treat-
ment. Models were replicated with adjustment for the propensity to
receive PPI, previously identified covariates for each outcome, and,
for landmark periods, the percentage of time the patient was on a PPI
up to the landmark period.
A time-dependent covariate analysis was also performed that
included the baseline characteristics from the previous models and
treatment. The time-dependent factors were PPI use and the interac-
tion of treatment with PPI.
Landmark methods were employed to adjust for changes in exposure
to PPIs after randomization. Landmark time periods considered began at
days 2, 4, 9, 30, 60, 90, and 180. PPI use was defined in each landmark
period as the status of PPI use closest to and including that landmark
date. The percentage of time the patient was on a PPI from randomiza-
tion to the start of the landmark is included as a covariate. For all
landmark analyses, patients who had the event after randomization but
before the landmark date were excluded.
We also performed further sensitivity analyses to assess specific
PPI subtypes, which may vary in their potential to inhibit CYP2C19,
and other gastric acid suppressive drugs, including H2 receptor
antagonists.
We performed efficacy analyses according to the intention-to-treat
principle. We undertook safety analyses for patients who received at
least 1 dose of study drug. Patients were followed for 12 months.
Rates of end points are expressed as Kaplan–Meier estimates. All
tests were 2-sided, with a significance value of P0.05; no correc-
tion for multiple testing was made. All statistical calculations were
performed with SAS, version 9.2 (SAS Institute, Cary, NC).
Results
Of the 18 624 patients enrolled in the PLATO trial, 18 601
(99.9%) had documentation regarding PPI use before ran-
domization, and 6539 (35.2%) were recorded to be taking a
PPI. The specific type of PPI most recently used at randomiza-
tion could be established in 6538 patients: 3200 (48.9%) on
omeprazole, 1967 (30.1%) on pantoprazole, 764 (11.7%) on es-
omeprazole, 510 (7.8%) on lansoprazole, and 97 (1.5%) on
rabeprazole. Baseline characteristics for patients who were or
were not on a PPI are shown in Table 1. Patients who were
treated with a PPI were more likely to have a prior history of
dyslipidemia, statin therapy, chronic renal disease, peripheral
arterial disease, percutaneous coronary intervention, coronary
artery bypass grafting, or chronic obstructive pulmonary
disease; were more likely to have an index diagnosis of
non–ST-segment elevation MI or to have higher Thrombol-
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ysis in Myocardial Infarction risk scores or Global Registry
of Acute Coronary Events mortality risk and to live in North
America; but were less likely to have prior congestive heart
failure and ST-segment depression than those not treated with
a PPI. Patients treated with a PPI before randomization were
also more likely to have a history of peptic ulcer disease and
lower baseline hemoglobin level. Baseline characteristics
between randomized treatment groups did not differ (data not
shown).
The median length of follow-up was 358 (25th, 75th percen-
tiles: 265, 369) days. The P value for the interaction between
randomized treatment and PPI use for the primary end point of
cardiovascular death/MI/stroke was not significant (P0.96).
For patients randomized to clopidogrel, the Kaplan–Meier rate
of the primary end point was 13.0% for individuals on a PPI at
the time of randomization (n3255) and 10.9% for those not on
a PPI (n6041) (unadjusted HR, 1.22; 95% CI, 1.08–1.39)
(Table 2 and Figures 1 and 2). For patients randomized to
Table 1. Patient Characteristics by Prior PPI Use at Baseline
Not Treated With PPI Treated With PPI P
Age, y* 62 (54–70) 63 (54–71) 0.001
Age 75 y 1776/12 060 (14.7) 1098/6539 (16.8) 0.001
Female 3477/12 062 (28.8) 1805/6539 (27.6) 0.078
Race 0.003
White 11 041/12 061 (91.5) 6015/6539 (92.0)
Black 141/12 061 (1.2) 88/6539 (1.4)
Asian 710/12 061 (5.9) 384/6539 (5.9)
Other 169/12 061 (1.4) 52/6539 (0.8)
Region 0.001
Europe, Middle East, Africa 8936/12 062 (74.1) 4908/6539 (75.1)
Asia, Australia 1080/12 062 (9.0) 629/6539 (9.6)
North America 1076/12 062 (8.9) 735/6539 (11.2)
Central America, South America 970/12 062 (8.0) 267/6539 (4.1)
History of
Dyslipidemia 5428/12 057 (45.0) 3526/6538 (49.8) 0.001
Previous statin 11 143/12 062 (92.4) 6317/6539 (96.6) 0.001
Hypertension 7884/12 058 (65.4) 4291/6538 (65.6) 0.73
Diabetes mellitus 2972/12 058 (24.7) 1689/6538 (25.8) 0.075
Chronic renal disease 454/12 058 (3.8) 331/6538 (5.1) 0.001
Peripheral arterial disease 698/12 058 (5.8) 446/6538 (6.8) 0.005
Cerebrovascular disease 765/12 057 (6.3) 387/6538 (5.9) 0.25
Myocardial infarction 2466/12 058 (20.5) 1357/6538 (20.8) 0.62
Congestive heart failure 747/12 058 (6.2) 303/6538 (4.6) 0.001
Percutaneous coronary intervention 1498/12 057 (12.4) 994/6538 (15.2) 0.001
Coronary artery bypass grafting 656/12 058 (5.4) 450/6538 (6.9) 0.001
Current smoker 4307/12 057 (35.7) 2366/6537 (36.2) 0.52
Chronic obstructive pulmonary disease 642/12 058 (5.3) 443/6538 (6.8) 0.001
Peptic ulcer disease 104/12 058 (0.9) 159/6538 (2.4) 0.001
Weight, kg* 80 (70–90) 80 (70–90) 0.13
Baseline hemoglobin, g/L* 141 (130–150) 138 (127–148) 0.001
Index event type 0.001
Unstable angina 2247/12 038 (18.7) 864/6530 (13.2)
STEMI 4493/12 038 (37.3) 2530/6530 (38.7)
NSTEMI 5010/12 038 (41.6) 2940/6530 (45.0)
Other 288/12 038 (2.4) 196/6530 (3.0)
Risk factors for STEMI
Killip class 2 39/4491 (0.9) 27/2528 (1.1) 0.405
TIMI risk score 3 1947/4493 (43.3) 1190/2530 (47.0) 0.003
Risk factors for NSTEMI
TIMI risk score 5 3067/7257 (42.3) 1781/3804 (46.8) 0.001
GRACE mortality risk* 0.017 (0.010–0.029) 0.017 (0.010–0.031) 0.001
Values in parentheses are percentages unless indicated otherwise. PPI indicates proton pump inhibitor; STEMI,
ST-segment elevation myocardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction; TIMI,
Thrombolysis in Myocardial Infarction; and GRACE, Global Registry of Acute Coronary Events.
*Values are median (25th, 75th percentiles).
980 Circulation February 28, 2012
 at FMRP SKANFO INC on April 10, 2013http://circ.ahajournals.org/Downloaded from 
ticagrelor, the rate of the primary end point was 11.0% for
individuals on a PPI (n3284) and 9.2% for those not on a PPI
(n6040) (unadjusted HR, 1.23; 95% CI, 1.07–1.41). After
adjustment for potential confounders and the propensity to be on
a PPI at randomization, a significant association remained
between use of a PPI and the primary end point both for patients
treated with clopidogrel (adjusted HR, 1.20; 95% CI, 1.04–1.38)
and for those treated with ticagrelor (adjusted HR, 1.24; 95% CI,
1.07–1.45) (interaction between randomized treatment and PPI
use P0.72). A time-dependent covariate analysis also demon-
strated a significant association between use of a PPI (versus no
PPI) and the primary end point (clopidogrel, adjusted HR, 1.45;
95% CI, 1.39–1.50; ticagrelor, adjusted HR, 1.44; 95% CI,
1.38–1.49). Ticagrelor compared with clopidogrel significantly
reduced the primary end point in patients (n12 060) without
PPI use before randomization (unadjusted HR, 0.84; 95% CI,
0.74–0.96), with a similar trend in the smaller subgroup
(n6539) of those with PPI use (unadjusted HR, 0.88; 95% CI,
0.74–1.03) (interaction P0.72).
Similarly, use of a PPI before randomization was associated
with numerically higher rates of cardiovascular death/MI, MI,
cardiovascular and all-cause mortality, and major (including
non–coronary artery bypass grafting) bleeding in both the
clopidogrel and ticagrelor groups (Table 2). The interaction
terms for PPI use and randomized treatment were not statisti-
cally significant for any of these end points. The risk of any MI
or stent thrombosis (definite, definite/probable, or definite/
probable/possible) was not significantly different on the basis
of the use of a PPI. Composite rates of major and minor
gastrointestinal bleeding were low and similar in both the
clopidogrel (no PPI: 1.2% and 0.3%, respectively; PPI: 1.4%
and 0.8%, respectively) and ticagrelor (no PPI: 1.0% and
0.3%, respectively; PPI: 1.2% and 0.6%, respectively)
groups.
Table 2. Kaplan–Meier Event Rates for 12-Month Efficacy and Safety End Points
Clopidogrel Ticagrelor P, Interaction
of Treatment
With PPI Use,
Unadjusted/
Adjusted
Treated With
PPI (n3255)
(%)
Not Treated
With PPI
(n6021) (%)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Treated With
PPI (n3284)
(%)
Not Treated
With PPI
(n6041) (%)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Cardiovascular
death, MI,
or stroke
398/3255 (13.0) 611/6021 (10.9) 1.22 (1.08–1.39) 1.20 (1.04–1.38) 337/3284 (11.0) 519/6041 (9.2) 1.23 (1.07–1.41) 1.24 (1.07–1.45) 0.96/0.72
All-cause death 213/3255 (7.3) 286/6021 (5.2) 1.38 (1.16–1.65) 1.5 (1.22–1.83) 146/3284 (4.7) 251/6041 (4.4) 1.08 (0.88–1.33) 1.10 (0.88–1.39) 0.07/0.05
Cardiovascular
death
180/3255 (6.0) 256/6021 (4.6) 1.31 (1.08–1.58) 1.42 (1.14–1.76) 125/3284 (4.1) 226/6041 (4.0) 1.03 (0.83–1.28) 1.13 (0.88–1.44) 0.10/0.17
Any MI 245/3255 (8.0) 354/6021 (6.5) 1.17 (0.96–1.42) 1.12 (0.9–1.4) 211/3284 (7.0) 292/6041 (5.2) 1.25 (1.01–1.55) 1.14 (0.89–1.45) 0.63/0.93
Cardiovascular
death/MI
378/3255 (12.4) 560/6021 (10.0) 1.27 (1.11–1.45) 1.25 (1.08–1.45) 308/3284 (10.0) 467/6041 (8.2) 1.24 (1.08–1.44) 1.26 (1.07–1.48) 0.84/0.94
Major bleed 363/3231 (12.5) 563/5953 (10.5) 1.22 (1.07–1.39) 1.2 (1.03–1.4) 356/3246 (12.3) 602/5989 (11.2) 1.11 (0.97–1.26) 1.05 (0.91–1.22) 0.31/0.22
Non-CABG major
bleed
127/3231 (4.4) 175/5953 (3.4) 1.36 (1.08–1.7) 1.30 (0.99–1.7) 140/3246 (4.9) 221/5989 (4.2) 1.18 (0.96–1.46) 1.02 (0.8–1.29) 0.39/0.17
Definite stent
thrombosis
46/2154 (2.2) 59/3495 (1.8) 1.30 (0.89–1.91) 1.19 (0.74–1.90) 30/2186 (1.5) 40/3454 (1.2) 1.16 (0.73–1.86) 1.17 (0.69–1.99) 0.71/0.97
Definite/probable/
possible stent
thrombosis
89/3238 (3.0) 121/5978 (2.3) 1.38 (1.05–1.82) 1.28 (0.93–1.76) 71/3257 (2.5) 88/6002 (1.6) 1.49 (1.10–2.04) 1.49 (1.04–2.12) 0.71/0.54
Unadjusted and adjusted hazard ratios (HR) (95% confidence intervals CI) indicating the association between proton pump inhibitor (PPI) use and the risk of clinical
outcomes are shown. MI indicates myocardial infarction; CABG, coronary artery bypass grafting.
Figure 1. Unadjusted cumulative Kaplan–
Meier estimates of the time to first occur-
rence of the primary end point (cardiovas-
cular [CV] death, myocardial infarction
[MI], or stroke) through follow-up by ran-
domized treatment and proton pump in-
hibitor (PPI) use.
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Use of a PPI before randomization was associated with a
higher rate of the composite primary end point at 30 days in
both the clopidogrel (unadjusted HR, 1.31; 95% CI, 1.10–
1.57; adjusted HR 1.46; 95% CI, 1.19–1.79) and ticagrelor
(unadjusted HR, 1.37; 95% CI, 1.13–1.65; adjusted HR, 1.45;
95% CI, 1.17–1.79) groups. The 30-day risk of stent throm-
bosis was not significantly different on the basis of the use of
a PPI (eg, definite thrombosis with clopidogrel [unadjusted
HR, 1.55; 95% CI, 0.98–2.44] and ticagrelor [unadjusted HR,
1.06; 95% CI, 0.60–1.86]).
Landmark analyses at days 2, 4, 9, 30, 60, 90, and 180
accounting for PPI use (median time to death or censoring 358
[266, 369] days) after randomization showed no significantly
higher risk of the primary end point in those receiving a PPI.
However, the trend for increased risk with PPI use remained
across most landmark periods, with no significant interactions
for PPI use with randomized treatment (Figure 3). When PPI use
over time was evaluated with an adjusted time-dependent cova-
riate model, PPI use was associated with an increased rate of the
primary outcome of similar magnitude for both clopidogrel and
ticagrelor (adjusted HR, 1.44; 95% CI, 1.39–1.50; adjusted HR,
1.45, 95% CI, 1.40–1.51, respectively).
Patients (n1826) on non-PPI gastrointestinal drugs (eg,
H2 receptor antagonists) before randomization had similar
rates of the primary outcome compared with those on a PPI
(PPI versus non-PPI gastrointestinal treatment: clopidogrel,
unadjusted HR, 0.98; 95% CI, 0.79–1.23; ticagrelor, unad-
justed HR, 0.89; 95% CI, 0.73–1.10). In contrast, patients
(n10 236) on no gastric therapy at randomization had a
significantly lower rate of cardiovascular death, MI, or stroke
(PPI versus no gastrointestinal treatment: clopidogrel, unad-
justed HR, 1.29; 95% CI, 1.12–1.49; ticagrelor, unadjusted
HR, 1.30; 95% CI, 1.14–1.49).
We performed additional analyses to assess the individual
types of PPIs and their associations with the primary out-
come. Primary end point event rates did not differ in patients
taking specific PPIs (including omeprazole) from those tak-
ing non-PPI gastrointestinal treatments before randomization.
In contrast, compared with patients on no gastrointestinal
treatment before randomization, those on omeprazole had a
significantly higher rate of the primary end point in both the
clopidogrel (unadjusted HR, 1.41; 95% CI, 1.19–1.68) and
ticagrelor (unadjusted HR, 1.33; 95% CI, 1.13–1.57) groups
(Table 3). Those on pantoprazole compared with those on no
gastrointestinal treatment also had a significantly higher rate
of the primary end point in the ticagrelor group (unadjusted
HR, 1.28; 95% CI, 1.04–1.56).
In addition, we examined the impact of the combined effect
of prior PPI status and carriage of CYP2C19 loss-of-function
alleles (*2 through *8) on the primary composite end point in
clopidogrel-treated patients (n4903) included in the genetic
substudy of the PLATO trial.32 The group of patients with any
loss-of-function alleles who were on a PPI (n434) had a
significantly higher cardiovascular death/MI/stroke rate than
those patients without any loss-of-function alleles or prior
PPI use (n2418): 7.8% versus 3.3% (unadjusted HR, 1.55;
95% CI, 1.15–2.09). Similarly, cardiovascular death/MI (7.6%
versus 2.9%; unadjusted HR, 1.63; 95% CI, 1.19–2.22), all-
cause mortality (2.5% versus 1.0%; unadjusted HR, 1.67; 95%
CI, 1.03–2.71), definite/probable stent thrombosis (2.6% versus
0.6%; unadjusted HR, 2.73; 95% CI, 1.37–5.43), and major
bleeding (8.0% versus 5.2%; unadjusted HR, 1.46; 95% CI,
1.08–1.96) were higher in those with loss-of-function alleles on
a PPI compared with those without any loss-of-function alleles.
Figure 2. Unadjusted and propensity-adjusted (for potential
confounders and the propensity to be on a proton pump inhibi-
tor [PPI] at randomization) hazard ratios, 95% confidence inter-
vals, and interaction P values (between randomized treatment
and PPI use) for the primary end point (cardiovascular [CV]
death, myocardial infarction [MI], stroke) and cardiovascular
death/MI by randomized treatment and PPI use. Figure 3. Landmark analyses from the time of randomization
accounting for proton pump inhibitor (PPI) use after randomiza-
tion with hazard ratios and 95% confidence intervals for the pri-
mary end point by randomized treatment and PPI use.
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Comparison with the primary outcome rates in the other 2
groups (loss-of-function alleles not on prior PPI [n954; 4.7%]
and no loss-of-function alleles on a PPI [n1097; 4.9%])
suggests that carriage of a loss-of-function allele was associated
with an increased risk of ischemic events in clopidogrel-treated
patients regardless of PPI use.
Discussion
In a large ACS population, the use of a PPI before randomization
was independently associated with a higher rate of the composite
of cardiovascular death/MI/stroke in patients receiving clopi-
dogrel. However, a similar association was observed between
cardiovascular events and PPI use during ticagrelor treatment
and with other non-PPI gastrointestinal treatment. Therefore, the
association between PPI use and adverse events appears highly
confounded such that PPI use is likely a marker for, rather than
a cause of, a higher rate of cardiovascular events.
Pharmacokinetic and pharmacodynamic studies, in which
in vitro platelet assays were used as surrogate end points,
suggest that concomitant use of a PPI and clopidogrel reduces
the antiplatelet effects of clopidogrel,3–8,10,33 irrespective of
timing of their administration.10 The strongest evidence for
such an interaction is between omeprazole and clopidogrel,
attributed to the fact that this PPI has a high potential to
inhibit the CYP2C19 isoenzyme and thus modulate conver-
sion of clopidogrel into its active metabolite. Previously,
several observational studies10,15–26,29,34,35 and 1 prospective
randomized trial36 found conflicting results with respect to
the association between concomitant PPI and clopidogrel use
and the risk of cardiovascular outcomes. In contrast to
clopidogrel and another thienopyridine, prasugrel, ticagrelor
is a P2Y12 inhibitor that does not require biotransformation
and has no known pharmacokinetic or pharmacodynamic
interaction with PPIs.14,30,31 However, in this trial, ticagrelor
and PPI use was associated with a similar increased rate of
cardiovascular events compared with ticagrelor and no PPI;
this finding was similar to that observed with clopidogrel and
PPI use. Furthermore, the use of a PPI was also associated
with an increased rate of major bleeding in the clopidogrel
group and a numeric but nonsignificantly higher rate in the
ticagrelor group. Although we did not adjust for potential
confounders with respect to the risk of bleeding, if PPIs
interfered with the metabolism of clopidogrel and ticagrelor
such that their reduced antiplatelet efficacy resulted in a
higher risk of subsequent ischemic events, it is otherwise
difficult to explain why these patients would also experience
a higher rate of bleeding. However, if the use of PPIs simply
identifies those patients at increased risk of cardiovascular
events, it is not surprising that these patients are also at higher
risk of major bleeding. We also observed a similar increased
rate of cardiovascular events in patients on non-PPI gastric
acid treatments; however, with the exception of cimetidine,
H2 antagonists are not known to interfere with ADP inhibitor
metabolism. In contrast, those patients on no gastrointestinal
therapies had a significantly lower primary end point rate.
Overall, the most plausible explanation for the apparent
association of both cardiovascular and bleeding events in both
the clopidogrel and ticagrelor groups with PPI use is that being
on a PPI is a marker for patients at higher risk of subsequent
events. An assessment of the baseline characteristics supports
the argument that patients on a PPI are at higher risk than those
not on a PPI, with a higher proportion of those of older age, with
prior comorbidities (cardiovascular and noncardiovascular re-
lated), and with higher mortality risk based on validated ACS
risk scores. Although statistical methods were employed to try to
adjust for potential confounders and the propensity to treat with
a PPI, it is well recognized that, in the absence of a randomized
allocation to PPI versus no PPI treatment, such an association
between increased rate of events and treatment falls well short of
an established cause-and-effect relationship.
The clopidogrel-PPI interaction is known to be a drug-specific
and not a class-specific effect depending on the degree of
interference with CYP2C19 activity.10 For example, omeprazole
is known to be a CYP2C19 inhibitor, whereas pantoprazole
appears to have a lower potential to inhibit CYP2C19, as
demonstrated by pharmacokinetic and pharmacodynamic as-
sessments.5–7,9,10,37 In addition, pantoprazole can also be metab-
olized outside the CYP system by a conjugating enzyme,
potentially accounting for lack of impact of pantoprazole on both
platelet aggregation and associated clinical outcomes.38 One
observational study15 found an association of clopidogrel and
PPIs that included omeprazole but not pantoprazole with an
increased rate of cardiovascular events; however, other stud-
ies22–24 found no difference between omeprazole or pantoprazole
in this respect. A recent trial showed similar cardiovascular rates
for those randomized to omeprazole plus placebo or omeprazole
plus clopidogrel,36 although the absolute number of cardiovas-
cular events was small and the release formulation of the
omeprazole-clopidogrel combination differs from that used in
routine clinical practice. We observed an apparent increased rate
Table 3. Unadjusted Hazard Ratios for Cardiovascular Death/Myocardial Infarction/Stroke by Randomized Treatment According to
Specific PPIs Compared With Non-PPI Gastrointestinal Treatment and No Gastrointestinal Treatment
PPI
vs Non-PPI Gastrointestinal Treatment vs No Gastrointestinal Treatment
Clopidogrel (n881) Ticagrelor (n945) Clopidogrel (n5140) Ticagrelor (n5096)
Any PPI* (n6538; 3254 clopidogrel, 3284 ticagrelor) 0.98 (0.79–1.23) 0.89 (0.73–1.10) 1.29 (1.12–1.49) 1.30 (1.14–1.49)
Omeprazole (n3200; 1592 clopidogrel, 1608 ticagrelor) 1.08 (0.84–1.37) 0.92 (0.73–1.15) 1.41 (1.19–1.68) 1.33 (1.13–1.57)
Pantoprazole (n1967; 973 clopidogrel, 994 ticagrelor) 0.86 (0.65–1.14) 0.88 (0.68–1.13) 1.13 (0.9–1.41) 1.28 (1.04–1.56)
Esomeprazole (n764; 387 clopidogrel, 377 ticagrelor) 0.86 (0.58–1.27) 0.92 (0.66–1.29) 1.13 (0.8–1.60) 1.34 (1.0–1.81)
Lansoprazole (n510; 251 clopidogrel, 259 ticagrelor) 1.08 (0.71–1.63) 0.77 (0.51–1.16) 1.41 (0.97–2.06) 1.12 (0.76–1.64)
Rabeprazole (n97; 51 clopidogrel, 46 ticagrelor) 0.81 (0.30–2.20) 1.02 (0.48–2.19) 1.06 (0.4–2.84) 1.49 (0.71–3.13)
*P value for the treatment by proton pump inhibitor (PPI) use interaction for the overall comparison of PPI vs non-PPI gastrointestinal treatment vs no gastrointestinal
treatment for cardiovascular death/myocardial infarction/stroke0.7815.
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of the primary end point in patients on omeprazole compared
with no PPI. However, this was evident in both the clopidogrel
and ticagrelor groups and similar to the rates associated with other
PPIs (eg, pantoprazole) and non-PPI gastrointestinal treatment.
In clopidogrel patients in the genetic substudy, we ob-
served the highest unadjusted event rates among those with
both CYP2C19 loss-of-function alleles and on prior PPI and
the lowest among those with neither loss-of-function alleles
nor PPI use; those with no loss-of-function alleles and prior
PPI use and with loss-of-function alleles but no prior PPI use
had event rates intermediate to the former 2 subgroups.
Particularly in the presence of CYP2C19 loss-of-function
alleles (eg, *2), it is possible that the use of a PPI could
further affect the metabolic, pharmacokinetic, and pharmaco-
dynamic response to clopidogrel. For example, among those
patients randomized to clopidogrel, there was a 1.5- to
2.7-fold increase in the unadjusted risk of cardiovascular
death/MI, all-cause mortality, and definite/probable stent
thrombosis for those with loss-of-function alleles on a prior
PPI compared with those without any loss-of-function alleles
on a PPI. However, major bleeding was also increased by
1.5-fold. Furthermore, a recent registry of patients adminis-
tered clopidogrel for a recent MI suggested that PPI use was
not associated with an increased risk of cardiovascular events
or mortality regardless of CYP2C19 status, although harm
could not be formally excluded in patients with 2 loss-of-
function alleles.27 Although our results are exploratory and
hypothesis generating, we speculate that these findings are
consistent with independent risks from loss-of-function car-
riage (in clopidogrel-treated patients) and the risk factors for
which PPI use is a marker (in both clopidogrel- and
ticagrelor-treated patients) of higher risk.
Given that a number of factors (eg, clinical characteristics,
drug-drug interactions, genetic polymorphisms) have the
potential to interfere with the formation of the active metab-
olite and pharmacodynamic effect (eg, high on-treatment
platelet reactivity) of clopidogrel, consideration for tailoring
antiplatelet treatment with newer P2Y12 receptor antagonists
has been raised. However, prospective randomized clinical
trials will be required to determine the utility of personalized
antiplatelet therapy. Furthermore, both prasugrel and ticagre-
lor have already been shown to be superior to clopidogrel in
a broad spectrum of ACS patients, regardless of PPI and
genetic status. Despite the fact that this is the largest pre-
specified assessment of PPI and ADP-receptor antagonist use
from a clinical trial population, our study has several limita-
tions. First, although this was a predefined subgroup analysis,
we undertook multiple comparisons within numerous sub-
groups. Second, the use of a PPI was not randomized, and the
potential for unmeasured and substantial residual confound-
ing, despite multivariable adjustment and propensity scoring
for the decision to treat with a PPI, cannot be underestimated.
Third, PPIs could be initiated or discontinued during the
course of follow-up, and although we employed landmark
and time-dependent analyses, we have no self-reported pa-
tient data regarding adherence. Fourth, there is limited evi-
dence that PPIs may interfere with the response to acetylsal-
icylic acid.39,40 Theoretically, this mechanism could account
for an increased risk of cardiovascular events associated with
the use of PPIs in both the clopidogrel and ticagrelor groups;
however, the data are conflicting in regard to this poten-
tial.40–44 Fifth, our analysis is derived from a clinical trial
population that specifically excluded some patients with high
bleeding risk and/or comorbidities such that the potential
impact of PPIs on clinical outcomes may differ when com-
pared with a more generalized population. Indeed, patients in
clinical trials tend to be younger and less likely to have diabetes
mellitus, renal dysfunction, and other comorbidities than those
included in previous observational studies examining this is-
sue.45 In this context, patients on PPI treatment, particularly
those with gastrointestinal symptoms, may also be more non-
compliant with ADP-receptor antagonist therapy, which could
be associated with a higher risk of ischemic events. Finally, we
are unable to exclude the possibility that a small component of
the observed increased risk in cardiovascular events was medi-
ated by a clopidogrel-PPI interaction.
In conclusion, the increased rate of cardiovascular events in
patients who receive a PPI seems to be explained mainly by
differences in baseline characteristics. The main strength and
novel contribution of our findings are derived from the fact that
the observed increased cardiovascular event rates associated
with PPIs and clopidogrel were also seen in patients randomized
to ticagrelor. Indeed, if the diminished antiplatelet effect of
clopidogrel, due to interference in metabolism by concomitant
PPI use, was to be the underlying mechanism accounting for the
associated increased rate of cardiovascular outcomes, then it is
difficult to account for the higher event rates also seen in the
ticagrelor group. Furthermore, these higher rates in cardiovas-
cular events were also observed in association with other
non-PPI gastrointestinal therapy. Finally, even major bleeding
rates were higher among PPI users. Therefore, in the PLATO
trial, the association between PPI use and adverse events may be
due to confounding, with PPI use more of a marker for, than a
cause of, higher rates of cardiovascular events. With recognition
of the inherent limitations of nonrandomized comparisons, our
findings do not support the need to avoid concomitant PPI use
with clopidogrel or ticagrelor.
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CLINICAL PERSPECTIVE
The clinical significance of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear. We examined
the relationship between prior PPI use and 1-year cardiovascular events in patients with acute coronary syndrome randomized
to clopidogrel or ticagrelor in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibition and Patient Outcomes
(PLATO) trial. The use of a PPI was independently associated with a higher rate of cardiovascular events in patients with acute
coronary syndrome receiving clopidogrel; however, a similar association was observed between cardiovascular events and PPI
use during ticagrelor treatment and with other non-PPI gastrointestinal treatment. Therefore, in the PLATO trial, the association
between PPI use and adverse events may be due to confounding, with PPI use more of a marker for, than a cause of, higher rates
of cardiovascular events. With recognition of the inherent limitations of nonrandomized comparisons, our findings do not support
the need to avoid concomitant PPI use with clopidogrel or ticagrelor.
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